uMotif

uMotif Harnesses AI to Deliver Faster, Higher-Quality Clinical Trials with MotifAI Assistant

Boston, US, and London, UK – November 3, 2025 –  uMotif – one of the clinical technology market’s fastest-growing companies – today announced a multi-phase deployment of MotifAI Assistant, its AI-driven automation, across its product portfolio. uMotif’s portfolio is anchored by modern, patient-first eCOA/ePRO, and enhanced by solutions for consent management, trial awareness, patient transport, and site productivity....

Life Science and Healthcare Industry Executive Adam Deutsch Joins uMotif Board as Company Brings the Next-Generation of eCOA/ePRO to Expanding Global Market

BOSTON, Mass. - March 15, 2023 óuMotif - one of the clinical trial technology marketís fastest growing companies - bolstered its status as the leader in next-generation eCOA/ePRO with the announcement that life science and healthcare executive Adam Deutsch has joined its Board of Directors.

uMotif Announces First New Validated Innovation in eCOA/ePRO Since Paper Instruments Were Deployed on Smartphones

Patent-protected Motif data capture interface proven as equivalent method to capture Patient Reported Outcome and eDiary data, eliminates reliance on text-based instruments, in study with 55 participants in 2 randomized groups conducted by SAFIRA Clinical Research at Dublin City University

uMotif ‚Ä’ the patient-first data capture and decentralized clinical trials platform ‚Ä’ announces $25.5m of new investment from a fund managed by Athyrium Capital Management

LONDON and NEW YORK, May 25, 2022-- uMotif today announced a new investment of $25.5m from a fund managed by Athyrium Capital Management, LP, the New York-based investment firm. The new funding will support continued scale up of uMotif's unique patient-first software platform for clinical research.
2th Floor, WeWork, 10 York Road, London, SE1 7ND, United Kingdom